Author

C. Sternberg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

F. Aberger· 3 shared L. Kenner· 3 shared R. Moriggl· 3 shared B. Tichy· 2 shared D. Lindner· 2 shared F. Sternberg· 2 shared H. A. Neubauer· 2 shared J. L. Persson· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. Aberger

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cell-autonomous GP130 activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment

C. Sternberg, T. Limberger, M. Raigel, K. Trachtova, M. Schlederer, D. Lindner, P. Kodajova, J. Yang, R. Ziegler, H. A. Neubauer, S. Dey, T. Redmer, S. Stoiber, V. Hejret, B. Tichy, , L. Kenner

This study shows that activating GP130 in prostate epithelial cells suppresses tumor growth through senescence and immune activation, suggesting a new therapeutic approach.

bioRxiv · Feb 11, 2024 · PreprintCancer Biology

JUN mediates senescence and immune cell recruitment to prevent prostate cancer progression

T. Redmer, M. Raigel, C. Sternberg, R. Ziegler, C. Probst, D. Lindner, A. Aufinger, T. Limberger, K. Trachtova, P. Kodajova, S. Hoegler, M. Schlederer, S. Stoiber, M. Oberhuber, M. Bolis, , L. Kenner

This study shows JUN suppresses prostate cancer progression by inducing senescence and immune cell recruitment, with JUN depletion accelerating tumor growth.

bioRxiv · Nov 29, 2023 · PreprintCancer Biology

STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pigmentation pathway

A. Swoboda, R. Soukup, K. Kinslechner, B. Wingelhofer, D. Schoerghofer, C. Sternberg, H. Pham, M. Vallianou, J. Horvath, D. Stoiber, L. Kenner, L. Larue, V. Poli, F. Beermann, T. Yokota, , R. Moriggl

This study shows that STAT3 promotes melanoma metastasis by repressing the MITF pigmentation pathway through CEBP induction.

Oncogene · Dec 15, 2020Peer-reviewedCancer Biology

Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells

D. P. Elmer, V. Strobl, G. Stockmaier, H.-H. Dang, M. Wiederstein, D. Licha, A. Strobl, C. Sternberg, S. Tesanovic, S. Grund-Groeschke, W. Gruber, F. Wolff, R. Moriggl, A. Risch, R. Reischl, , F. Aberger

This study identifies IDO1-kynurenine pathway activation as a novel mechanism by which HH-IL6 and GLI-STAT signaling promote immunosuppression in skin cancer, suggesting combination therapy targeting these pathways.

bioRxiv · May 4, 2020 · PreprintCancer Biology